DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor five-year survival rate of less than 10%. Immune suppression along with chemoresistance are obstacles for PDAC therapeutic treatment. Innate immune cells, such as tumor-associated macrophages, are recruited to the inflammatory environment...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakkina, Sai Preethi, Gitto, Sarah B., Beardsley, Jordan M., Pandey, Veethika, Rohr, Michael W., Parikh, Jignesh G., Phanstiel, Otto, Altomare, Deborah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706739/
https://www.ncbi.nlm.nih.gov/pubmed/34947972
http://dx.doi.org/10.3390/ijms222413175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706739/
https://www.ncbi.nlm.nih.gov/pubmed/34947972
http://dx.doi.org/10.3390/ijms222413175

Ejemplares similares